Literature DB >> 32701706

Differential Expression of Cancer Testis Antigens on Lentigo Maligna and Lentigo Maligna Melanoma.

Darryl Tio1, Marcella Willemsen1, Gabrielle Krebbers1, Fazira R Kasiem1, Rick Hoekzema1, Remco van Doorn2, Marcel W Bekkenk1, Rosalie M Luiten1.   

Abstract

The cancer/testis antigens (CTA) are a group of antigens expressed on germ cells of healthy testis and malignant tumors. We studied whether CTA are present on lentigo maligna (LM) and LM melanoma (LMM) samples. Immunohistochemical expression of a panel of CTA (MAGE-A1, A2- A3, NY-ESO-1, PRAME, SSX-2, and a MAGE-A antibody reactive with -A1, -A2, -A3, -A4, -A6, -A10, and -A12) was investigated in formalin-fixed paraffin-embedded samples from LMM (n = 20), LM (n = 8), chronically sun-exposed skin (n = 7), and healthy skin (n = 7). In 4 LMM lesions, the MAGE-A marker was positive. Another 3 LMM lesions were positive for MAGE-A1, MAGE-A2, and MAGE-A3. PRAME was positive in 18/20 LMM and 6/8 LM. We did not find expression of MAGE, NY-ESO-1, or SSX-2 in LM, thereby excluding these CTA as diagnostic markers to discern malignant melanocytes in LM from normal melanocytes. LMM did express MAGE, NY-ESO-1, and SSX-2. If a biopsy from a lesion suspect for LM shows positivity for MAGE, NY-ESO-1, and SSX-2, the lesion may actually be LMM. In contrast, PRAME expression was found in LM at low levels and in LMM at much higher levels, and absent in normal melanocytes. PRAME can potentially be used to discern normal melanocytes from malignant melanocytes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32701706     DOI: 10.1097/DAD.0000000000001607

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

Review 1.  PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.

Authors:  Cecilia Lezcano; Achim A Jungbluth; Klaus J Busam
Journal:  Surg Pathol Clin       Date:  2021-04-28

2.  The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study.

Authors:  Yu-Xin Wang; Feng-Lian Li; Li-Xin Du; Jun-Fang Liu; Li-Gang Huo; Shu-Qing Li; Bin Tian
Journal:  Cancer Manag Res       Date:  2021-08-04       Impact factor: 3.989

Review 3.  Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.

Authors:  Gerardo Cazzato; Katia Mangialardi; Giovanni Falcicchio; Anna Colagrande; Giuseppe Ingravallo; Francesca Arezzo; Giovanna Giliberti; Irma Trilli; Vera Loizzi; Teresa Lettini; Sara Scarcella; Tiziana Annese; Paola Parente; Carmelo Lupo; Nadia Casatta; Eugenio Maiorano; Gennaro Cormio; Leonardo Resta; Domenico Ribatti
Journal:  Genes (Basel)       Date:  2022-03-19       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.